Trust Homepage > Pathology Homepage

Test and Tubes Database
ID:77 Digoxin
Search Links: General Info : Protocols : Patient Info

DescriptionFor monitoring purposes, blood should not be drawn until a steady state has been attained. This will not be achieved until 1-3 weeks after starting therapy or changing dose.
IndicationRoutine monitoring not necessary on patients on maintenance dose if satisfactory response and no toxicity.
Additional InfoFor monitoring purposes, blood should not be drawn until a steady state has been attained. This will not be achieved until 1-3 weeks after starting therapy or changing dose. Hypercalcaemia, hypomagnasaemia and hypothyroidism may increase sensitivity as will other causes of hypokalaemia e.g diarrhoea, corticosteroids, carbenoxolone. INDICATIONS FOR MONITORING: a) Initial poor response to treatment - serum digoxin will indicate level achieved and provide guidance on dosage increase b) Helping to confirm diagnosis of toxicity although concomitant hypokalaemia must be taken into account c) When previous drug history is uncertain particularly in elderly patients receiving a number of drugs d) To facilitate discontinuation of therapy e) When renal function is deteriorating or fluctuating f) when drugs known to interfere or interact with digoxin are started or stopped e.g Verapamil and digoxin in intractable SVT- digoxin may be used at reduced dose.
Concurrent Testsna
Dietary Requirementsna

InterpretationReference range is only applicable for normokalaemic patients. If patient is hypokalaemic digoxin toxicity can occur when levels are within the reference range. Reduce dose if renal function is poor. NOTE: Reporting units changed from nmol/L to microgram/L May 1, 2007. NB: drugs which can cause INCREASED serum digoxin levels include: amiodarone, anticholinergic drugs, diltiazem, propafenone, quinidine, spironolactone, verapamil. Drugs which can cause DECREASED serum digoxin levels include: antacids, cholestyramine, domperidone, kaolin-pectin, metoclopramide, sulfasalazine

Ref. Range (Male)0.5 - 1.0 microgram/L
Ref. Range (Female) 0.5 - 1.0 microgram/L
Ref. Range (Paed)
Ref. Range Notes1: Reporting units changed from nmol/L to microgram/L May 1, 2007. 2: Change in advised therapeutic range Nov 5, 2008.
Unitsug/L


IP Acute TATRefer to Website
IP Routine TATRefer to Website
GP Acute TAT- Contact Laboratory
GP Routine TATRefer to Website
Turnround CommentNA
Originally edited by : MC. Last edited on 12/01/2018 18:30:03. Published By Sylvia Bennett on 12/01/2017 18:30:03.